Document is current
Any future updates will be listed below
-
Authors
Aoki, Joni A.
Denorme, Frederik
Cody, Mark J.
Perry, David P.
Rustad, John L.
Brown, Samuel M.
Goldstein, Stephanie A.
Middleton, Elizabeth A.
Yost, Christian C.
Harris, Estelle S.
,
-
Funding
Funding for this research was provided by:
American Heart Foundation (24SCEFIA1262494)
National Heart, Lung, and Blood Institute (KO8HL153953)
National Institute of Child Health and Human Development (R01HD09382)
- License Information
-
More Information
Article History
Received: 13 December 2024
Accepted: 22 May 2025
First Online: 13 June 2025
Declarations
:
: This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki, ensuring the protection of all human participants through informed consent, risk–benefit analysis, and appropriate safeguards for vulnerable populations.The PETAL Pathogenesis Committee approved this study as an ancillary NET study in October of 2020, and provided the samples to the University of Utah in July of 2021. We obtained plasma samples from 200 randomly chosen study participants who survived for at least forty-eight hours. The PETAL Pathogenesis Committee ensured that all ROSE trial plasma samples and clinical information were de-identified prior to arrival at the University of Utah. We also collected plasma from twenty healthy donors enrolled by our laboratory using our institutional protocol at the University of Utah for blood sampling of healthy volunteers (IRB# 0051506).
: Not applicable.
: The authors declare no competing interests.
